文献速递前列腺增生与排尿功能障碍

经会阴激光消融治疗良性前列腺增生:更新的系统综述与汇总分析

Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-03-12

该系统综述纳入17项研究,其中2项随机对照试验比较经会阴前列腺激光消融(TPLA)与经尿道前列腺电切术(TURP),12项前瞻性和3项回顾性非随机研究(其中1项比较TPLA与前列腺动脉栓塞(PAE))。TPLA主要发生低级别并发症(Clavien-Dindo分级≤II),无重大不良事件(CD分级>III),术后5年内泌尿功能显著改善,勃起与射精功能未受显著影响。

要点

  • TPLA主要发生低级别并发症(CD≤II),未见CD>III的重大不良事件。
  • TPLA术后泌尿功能改善可持续至术后5年,勃起与射精功能未受显著影响。
  • 现有证据仍有限,需更大规模前瞻性对照研究证实TPLA疗效并与标准内镜技术比较。

核心结论

  • TPLA在短期和中期显示出良好结果,可改善泌尿功能、保留性功能并维持良好安全性。
  • 由于现有证据仍有限,需更大规模前瞻性对照研究以证实TPLA疗效,并与标准内镜技术及其他微创手术充分比较。

研究设计与样本

  • 系统综述与汇总分析,检索PubMed、Embase和Cochrane Central数据库,检索日期为2024年6月12日,遵循EAU指南办公室与PRISMA声明建议。
  • 共纳入17项研究:2项随机对照试验比较TPLA与TURP,12项前瞻性和3项回顾性非随机研究,其中1项比较TPLA与前列腺动脉栓塞(PAE)。
  • 所有手术均使用同一EchoLaserTM系统(SoracteLiteTM)(Elesta s.r.l.,意大利卡伦扎诺(FI))。

主要发现

  • 主要报告低级别并发症(Clavien-Dindo分级≤II),未发生重大不良事件(CD分级>III)。
  • 在所有研究中,TPLA均带来泌尿功能的显著改善,效果持续至术后5年。
  • TPLA对勃起功能和射精功能无显著影响。
  • 纳入标准、围手术期与术后管理方面存在很大异质性。

局限性

  • 由于现有证据仍有限,需更大规模前瞻性对照研究以证实TPLA疗效并与标准内镜技术及其他微创手术充分比较。
  • 纳入标准、围手术期与术后管理方面存在很大异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Standard surgical options for Benign Prostatic Hyperplasia [BPH], despite their excellent functional outcomes, are associated with multiple side effects and require general/spinal anesthesia and hospitalization. In this scenario, Transperineal Laser Ablation of the Prostate [TPLA] emerged as an ultra-minimally invasive ejaculation-sparing procedure, showing promising functional results, with a good safety profile. This systematic review aimed to provide an overview of the current role of TPLA in clinical practice, focusing on operative setting, safety, and efficacy. EVIDENCE ACQUISITION: Literature search was performed on June 12th, 2024 using PubMed, Embase, and Cochrane Central databases, following the EAU Guidelines Office and the PRISMA statement recommendations. All studies reporting outcomes after TPLA procedures were included. EVIDENCE SYNTHESIS: Seventeen studies were included in this systematic review, of which 2 RCTs compared TPLA with TURP, 12 prospective and 3 retrospective non-randomized studies (of which 1 comparing TPLA and Prostatic Artery Embolization [PAE]). All procedures were performed using the same EchoLaserTM system (SoracteLiteTM) (Elesta s.r.l., Calenzano (FI), Italy), however great heterogeneity exists considering inclusion criteria, peri- and post-operative management. Mainly low-grade complications (Clavien-Dindo [CD] Grade ≤ II) were reported, while no major adverse events (CD grade > III) occurred. In all studies TPLA led to a great improvement in urinary function, up to 5 years after the procedure, while not significantly impacting erectile and ejaculatory functions. CONCLUSIONS: TPLA showed promising results both in the short- and mid-term, improving urinary function while preserving sexual function and keeping a good safety profile. Since the evidence available is still limited, larger prospective comparative studies are warranted to confirm the efficacy of TPLA and to adequately compare it to standard endoscopic techniques and other minimally invasive surgical treatments.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Alberti A, Lo Re M, Nicoletti R, et al. Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis. Prostate Cancer Prostatic Dis. 2025. PMID: 40074835. doi:10.1038/s41391-025-00952-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。